EHEdward D. Huey

Edward D. Huey

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Edward D. Huey has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Brain Regions Involved in Arousal and Reward Processing are Associated with Apathy in Alzheimer’s Disease and Frontotemporal Dementia

    by Edward D. Huey, For The Alzheimer’S Disease Neuroimaging Initiative, Seonjoo Lee, Gayathri Cheran, Jordan Grafman, Davangere P. Devanand

    Background: Apathy is a common and problematic symptom of several neurodegenerative illnesses, but its neuroanatomical bases are not understood. Objective: To determine the regions associated with apathy in subjects with mild Alzheimer’s disease (AD)


  • Caregiver Burden in Frontotemporal Degeneration and Corticobasal Syndrome

    by Nicole Armstrong, Nicole Schupf, Jordan Grafman, Edward D. Huey

    Background and Aims: Caregiver stress is often a serious problem when caring for a patient with frontal lobe dysfunction. Methods: A total of 102 caregivers of both patients with frontotemporal degeneration and corticobasal syndrome completed the Frontal Systems Behavior Scale (FrSBe) and the Zarit Burden Interview (ZBI). To analyze the association between apathy or disinhibition (or both) and caregiver burden, the effects of the total FrSBe and the apathy and disinhibition subscales of the FrSBE on the total ZBI score were assessed with logistic regressions and t tests. Results: Total FrSBE score and the apathy FrSBE subscore predicted caregiver burden. Apathy occurred without disinhibition, and the two occurred together, but disinhibition without apathy was very rare. Conclusions: Disinhibition without apathy occurred very rarely. Apathy was more associated with caregiver burden than disinhibition.


  • Management of frontotemporal dementia in mental health and multidisciplinary settings

    by Mary Anne Wylie, Adriana Shnall, Chiadi U. Onyike, Edward D. Huey

    Diagnosis of frontotemporal dementia (FTD) in the mental health setting and issues pertaining to longitudinal care of this population in a specialist clinic are reviewed. FTD is often misdiagnosed as a psychiatric disorder, most commonly as a mood disorder. FTD has features that overlap with those of major depression, mania, obsessive–compulsive disorder and schizophrenia. We describe these features and how to differentiate FTD from these psychiatric disorders. This paper also describes practical issues in the management of FTD, specifically the issues that clinicians, patients and their families face in managing this disease. Areas of clinical care along the continuum are explored; FTD care involves collaborative management of symptoms and disability, and assisting patients and families in adapting to the disease.


  • C9ORF72 repeat expansions not detected in a group of patients with schizophrenia

    by Edward D. Huey, Peter L. Nagy, Laura Rodriguez-Murillo, Masood Manoochehri, Jill Goldman, Jeffrey Lieberman, Maria Karayiorgou, Richard Mayeux


  • Course and etiology of dysexecutive MCI in a community sample

    by Edward D. Huey, Jennifer J. Manly, Ming‐X. Tang, Nicole Schupf, Adam M. Brickman, Masood Manoochehri, Jesse Mez, Charles DeCarli, Davangere P. Devanand, Richard Mayeux

    Background: Amnestic mild cognitive impairment (aMCI) is associated with an elevated risk of progressing to Alzheimer's disease. Much less is known about the course of dysexecutive mild cognitive impairment (dMCI). The goals of this study were to determine how the profile of cognitive deficits differs over time between patients with dMCI and aMCI, and control subjects; if the type of dementia differs between dMCI and aMCI in patients who progress to dementia; and if dMCI is more associated with stroke and white matter hyperintensity on magnetic resonance imaging (MRI) than aMCI.Methods: The authors undertook a prospective evaluation of an inception cohort of 1167 ethnically diverse elders recruited from an urban community‐based sample monitored with clinical and neuropsychological testing for an average of 4.5 years (standard deviation, 0.8 year). A subset of the subjects underwent MRI. We compared four groups of MCI patients: single‐domain amnestic and dysexecutive MCI, and multiple‐domain MCI with and without executive dysfunction.Results: Compared with aMCI, dMCI was less likely to involve other areas of cognition over time and progress to dementia. None of the 33 single‐domain dMCI patients progressed to dementia. The presence of executive dysfunction in multiple‐domain MCI did not increase risk of progression to dementia. Patients with multiple‐domain MCI with executive dysfunction who progressed to dementia were less likely to have an Alzheimer's–type dementia than MCI patients without executive dysfunction. Patients with dMCI were more likely to experience stroke, but not white matter hyperintensity, detected via MRI than patients with aMCI.Conclusions: dMCI appears to follow a different course, and is less associated with Alzheimer's disease and more associated with stroke than aMCI.


  • Diagnosis and Management of Behavioral Issues in Frontotemporal Dementia

    by Masood Manoochehri, Edward D. Huey

    Frontotemporal lobar degeneration is an umbrella term for several different disorders. In behavioral variant frontotemporal dementia (bvFTD), patients show deterioration in cognition and social behavior. New diagnostic criteria proposed by the International Behavioral Variant FTD Consortium provide greater sensitivity in diagnosing bvFTD. Current pharmacological management of symptoms relies on medications borrowed from treating Alzheimer’s disease (AD) and psychiatric disorders. The evidence for using AD medications such as acetylcholinesterase inhibitors is questionable. Psychiatric medications can be helpful. Trazodone or SSRIs can have some efficacy in reducing disinhibition, repetitive behaviors, sexually inappropriate behaviors, and hyperorality. Small doses of atypical antipsychotics may be helpful in decreasing agitation and verbal outbursts. Nonpharmacological management includes caregiver education and support and behavioral interventions. While symptomatic treatments are likely to remain important behavior management tools, targeting the underlying pathology of bvFTD with disease-modifying agents will hopefully be the future of treatment.